Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact email@example.com.
COVID‐19 Vaccine Efficacy and the Evidence on Boosters
23 Pages Posted: 30 Dec 2021More...
Background: The need for COVID‐19 vaccine booster shots is controversial. Krause et al. and others have argued that need for a COVID‐19 booster for all adults has not been sufficiently established. The EU, UK, Canada, and Israel approved boosters for all adults, but U.S. regulators initially limited booster eligibility, waited nearly two months before allowing, and even longer before recommending boosters for all adults, with public health officials sending mixed messages on booster value.
Methods: We summarize vaccine efficacy against four endpoints: any infection, symptomatic infection, hospitalization, and death for the four principal vaccines used in developed Western countries (BNT162b2, mRNA1273, Ad26.CoV2.S, and ChAdOxS‐1), and evidence for waning efficacy over time, based on review of regulatory submissions and studies which met defined inclusion criteria.
Findings: Evidence on vaccine efficacy across multiple studies supports the conclusions that: (i) the mRNA vaccines experience significant declining efficacy after approximately six months, especially against infection but also against severe disease, with Pfizer declining faster than mRNA1273, but (ii) both mRNA vaccines outperform the Ad26.CoV2.S and ChAdOx1‐S viral vector vaccines. Booster doses greatly strengthen antibody levels and reduce both symptomatic infection and severe disease.
Interpretation: Strong epidemiological evidence supports the value of a booster dose for COVID vaccines, roughly 6 months after initial vaccination. Boosters both protect those who receive them and provide large spillover benefits to others, both vaccinated and unvaccinated, by preventing downstream infections, some of which will lead to hospitalization and death; reducing shortage risk for monoclonal antibodies, antiviral medications and other currently scarce COVID treatments; and reducing hospital overload (and thus improving survival rates. The emergence of the Omicron variant strengthens their value. Comprehensive evaluation of vaccination dosage and timing, including boosters, are part of proactive public health response to COVID risk.
Funding Information: No outside funding.
Declaration of Interests: None of the authors have any conflicts to disclose.
Ethics Approval Statement: Our study does not involve human subjects research and is exempt from review by an institutional review board.
Keywords: COVID-19, SARS-CoV-2, vaccine, vaccine efficacy, vaccine booster, BNT162b2, mRNA1273, Ad26.COV2.S, ChAdOxS-1, SARS-CoV-2 variants
Suggested Citation: Suggested Citation